Moderna's vaccine against respiratory syncytial virus (RSV) was 83 percent effective at preventing lower respiratory tract disease in adults aged 60 and older in a large clinical trial, the company announced on Tuesday. Based on the results, Moderna said it intends to submit the vaccine for Food and Drug Administration (FDA) approval in the first half of 2023. The announcement puts Moderna into a crowded marketplace of RSV vaccines for older adults, including giants GlaxoSmithKline and Pfizer. Both companies have applied for FDA approval of their respective RSV vaccines and expect decisions in May. Moderna said the vaccine was 83.7 percent effective at preventing two key symptom
Hence then, the article about moderna says rsv vaccine is effective in older adults was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Moderna says RSV vaccine is effective in older adults )